Treatments for Inflammatory and Neoplastic Skin Diseases
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".
Deadline for manuscript submissions: 31 May 2024
Special Issue Editor
2. Dermatology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy
Interests: melanoma; dermatology; dermatoscopy; hidradenitis suppurativa; acne
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the last 15 years, the advent of biologics has revolutionized the treatment of psoriasis. After the first anti-tnf-alfa drugs, biosimilars are now also available; the anti-interleukin groups (anti-IL-17 and anti-IL-23) are safe and effective treatments for most psoriatic patients, even those with difficult-to-treat body areas.
Further, the management of atopic dermatitis has changed thanks to dupilumab and, subsequently, tralokinumab and the inhibitors of Janus kinases. In the near future, many other drugs, both biologics and small molecules, will be marketed for several skin diseases, including vitiligo, alopecia areata and hidradenitis suppurativa.
In the field of Dermato-Oncology, immunotherapy and targeted therapies are currently used for difficult-to-treat locally advanced basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and melanoma. Sharing experiences of these treatments will enhance the knowledge and confidence of dermatologists.
Early diagnosis is crucial for timely assessment of patients, so as to seek the best treatment plan and improve the patient's condition.
For this Special Issue, we expect reviews and original research on new approaches to the diagnosis and management of skin tumors. We welcome contributions that provide clinicians with the latest research advances and insights.
Dr. Gianluca Nazzaro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dermatology
- dermatological diseases
- skin
- psoriasis
- atopic dermatitis
- hidradenitis suppurativa
- alopecia areat
- vitiligo
- squamous cell carcinoma (SCC)
- basal cell carcinoma (BCC)
- melanoma
- diagnostic
- treatment
